Company Filing History:
Years Active: 2011-2017
Title: Innovations in Cancer Treatment by Inventor Josef Michl
Introduction
Josef Michl is a notable inventor based in Little Neck, NY (US), recognized for his significant contributions to cancer treatment through innovative pharmaceutical compositions. With a total of four patents to his name, Michl's work focuses on developing targeted therapies that selectively affect cancer cells while sparing normal cells.
Latest Patents
Among his latest patents, Michl has developed small molecule cancer treatments that induce necrosis in cancer cells without harming normal cells. This method involves administering a therapeutically effective amount of a composition that includes an HDM-2 binding component and a membrane resident component. Additionally, he has created a method for selectively necrosing cancer cells and a cancer treatment composition that enhances the efficacy of these therapies. Another significant patent addresses the phenotypic reversion of pancreatic carcinoma cells. This invention provides peptides that correspond to specific residues of ras-p21, which have been shown to induce a transformation of cancerous cells back to non-cancerous states. The pharmaceutical compositions derived from these peptides offer promising avenues for cancer treatment.
Career Highlights
Josef Michl's career is marked by his dedication to advancing cancer research and treatment methodologies. His innovative approaches have garnered attention in the scientific community, leading to the development of therapies that could potentially change the landscape of cancer treatment.
Collaborations
Throughout his career, Michl has collaborated with esteemed colleagues, including Matthew R. Pincus and Ehsan Sarafraz-Yazdi. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.
Conclusion
Josef Michl's contributions to cancer treatment through his innovative patents highlight the potential for targeted therapies in improving patient outcomes. His work continues to inspire advancements in the field of oncology.